License and Research Agreements - Regeneron - Additional Information (Details) - USD ($) $ in Millions |
1 Months Ended | 12 Months Ended | 54 Months Ended | 67 Months Ended | |
|---|---|---|---|---|---|
Jan. 31, 2022 |
Dec. 31, 2024 |
Jun. 30, 2026 |
Jun. 30, 2026 |
Dec. 31, 2025 |
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Regulatory milestone payments achieved | $ 30 | $ 9 | |||
| Regeneron Pharmaceuticals Inc | |||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Upfront payments of collaboration | $ 30 | ||||
| Regulatory milestone payments achieved | $ 33 | ||||
| Eligible future milestone payments | 31 | 31 | |||
| Accrued collaboration payables | $ 5 | $ 5 | $ 9 | ||
| Maximum | Regeneron Pharmaceuticals Inc | |||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Profit loss sharing percentage on net sales | 40.00% | ||||
| Minimum | Regeneron Pharmaceuticals Inc | |||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Profit loss sharing percentage on net sales | 20.00% |